NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD
EBS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While EBS seems to be doing ok healthwise, there are quite some concerns on its profitability. EBS has a valuation in line with the averages, but on the other hand it scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.23% | ||
ROE | -23.81% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 35.33% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.2 | ||
Debt/FCF | 7.05 | ||
Altman-Z | 1.13 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 6.32 | ||
Quick Ratio | 3.51 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 4.74 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 4.19 | ||
EV/EBITDA | 24.75 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
7.28
+0.29 (+4.15%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 4.74 | ||
P/S | 0.41 | ||
P/FCF | 4.19 | ||
P/OCF | 3.59 | ||
P/B | 0.71 | ||
P/tB | 5.85 | ||
EV/EBITDA | 24.75 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.23% | ||
ROE | -23.81% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 35.33% | ||
FCFM | 9.78% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.2 | ||
Debt/FCF | 7.05 | ||
Debt/EBITDA | 18.39 | ||
Cap/Depr | 14.77% | ||
Cap/Sales | 1.63% | ||
Interest Coverage | N/A | ||
Cash Conversion | 304.14% | ||
Profit Quality | N/A | ||
Current Ratio | 6.32 | ||
Quick Ratio | 3.51 | ||
Altman-Z | 1.13 |